SCHEMBL2830203

SCHEMBL2830203

CCCOn1c(C)c(C(=O)O)c2cccc(Cl)c2c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.39
CNR1 P21554 2/20 0.38
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ATM Q13315 1/20 0.35
RORC P51449 1/20 0.34
DHODH Q02127 2/20 0.34
MAP4K4 O95819 1/20 0.34
CSF1R P07333 1/20 0.34
PIM1 P11309 1/20 0.34
MAPK8 P45983 1/20 0.34
MAPK9 P45984 1/20 0.34
CLK2 P49760 1/20 0.34
MAPK10 P53779 1/20 0.34
MAP4K2 Q12851 1/20 0.34
MINK1 Q8N4C8 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2832957 0.90 CNR2 (0.38) CNR2CNR1ALDH1A1TSHRKMT2A
SCHEMBL2832580 0.86 ALDH1A1 (0.36) CNR2CNR1ALDH1A1TSHRKMT2A
SCHEMBL2835066 0.85 ALDH1A1 (0.40) CNR2CNR1ALDH1A1TSHRKMT2A
SCHEMBL2153849 0.82 TACR3 (0.44) ALDH1A1TSHRKMT2AMEN1ATM
SCHEMBL2832139 0.79 CNR2 (0.55) CNR2CNR1ALDH1A1TSHRKMT2A
SCHEMBL2830806 0.76 CNR2 (0.39) CNR2CNR1KMT2AMEN1RORC
SCHEMBL2837533 0.76 RORC (0.39) CNR2CNR1KMT2AMEN1RORC
SCHEMBL2831445 0.76 CNR2 (0.41) CNR2CNR1KMT2AMEN1ATM
SCHEMBL2830990 0.76 MEN1 (0.36) ALDH1A1TSHRKMT2AMEN1ATM
SCHEMBL1036361 0.74 RORC (0.51) ALDH1A1KMT2AMEN1ATMRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 CNR2 359/4885CNR1 361/4885ALDH1A1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.